"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line"
Circulating plasma GLP-1 levels rise from approximately 510 pmol/L in the fasted state to 1550 pmol/L in the postprandial state, with peak levels depending on meal composition, caloric density, and rate of gastric emptying
Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies
The flexible linker ensures spatial separation between the Fc region and the GLP-1 receptorbinding domain, preserving receptor accessibility and bioactivity
A Perfect Fit: GLP-1 and Remote Weight Monitoring Remote weight monitoring has the potential to be a linchpin in helping ensure that GLP-1 therapies reach their full therapeutic potential
Earlier versions of GLP-1 drugs, such as exenatide (Byetta), increased the risk for pancreatic cancer or certain types of thyroid cancer and even instances of autoimmunity
